Q1 2025 Earnings Forecast for Bio-Techne Co. (NASDAQ:TECH) Issued By Leerink Partnrs

Bio-Techne Co. (NASDAQ:TECH) – Equities research analysts at Leerink Partnrs reduced their Q1 2025 earnings estimates for shares of Bio-Techne in a research report issued on Wednesday, September 18th. Leerink Partnrs analyst P. Souda now forecasts that the biotechnology company will earn $0.34 per share for the quarter, down from their prior forecast of $0.36. The consensus estimate for Bio-Techne’s current full-year earnings is $1.71 per share. Leerink Partnrs also issued estimates for Bio-Techne’s Q2 2025 earnings at $0.34 EPS, FY2025 earnings at $1.69 EPS, Q1 2026 earnings at $0.44 EPS, Q2 2026 earnings at $0.45 EPS and Q4 2026 earnings at $0.62 EPS.

Several other analysts have also weighed in on the company. Robert W. Baird raised their price objective on Bio-Techne from $81.00 to $82.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Benchmark reaffirmed a “buy” rating and set a $95.00 price target on shares of Bio-Techne in a report on Tuesday, August 13th. Citigroup downgraded shares of Bio-Techne from a “buy” rating to a “neutral” rating and set a $85.00 price objective for the company. in a research note on Wednesday, May 22nd. Finally, Royal Bank of Canada reduced their price target on Bio-Techne from $72.00 to $70.00 and set a “sector perform” rating on the stock in a report on Thursday, August 8th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Bio-Techne currently has an average rating of “Moderate Buy” and an average target price of $80.60.

Bio-Techne Trading Up 1.6 %

Shares of TECH stock opened at $76.51 on Thursday. Bio-Techne has a fifty-two week low of $51.79 and a fifty-two week high of $85.57. The stock’s fifty day moving average price is $75.15 and its two-hundred day moving average price is $73.92. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.75 and a current ratio of 3.87. The company has a market cap of $12.14 billion, a PE ratio of 60.72, a P/E/G ratio of 5.06 and a beta of 1.27.

Bio-Techne (NASDAQ:TECH) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.49 EPS for the quarter, hitting analysts’ consensus estimates of $0.49. The firm had revenue of $306.10 million for the quarter, compared to analyst estimates of $306.49 million. Bio-Techne had a return on equity of 12.88% and a net margin of 14.50%. The company’s revenue was up 1.6% on a year-over-year basis. During the same quarter last year, the company earned $0.56 EPS.

Bio-Techne Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, August 30th. Shareholders of record on Monday, August 19th were given a dividend of $0.08 per share. This represents a $0.32 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date was Monday, August 19th. Bio-Techne’s dividend payout ratio is presently 25.40%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP raised its stake in Bio-Techne by 19.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 734,105 shares of the biotechnology company’s stock worth $56,646,000 after buying an additional 118,534 shares during the last quarter. Sei Investments Co. boosted its position in shares of Bio-Techne by 16.2% during the 4th quarter. Sei Investments Co. now owns 856,514 shares of the biotechnology company’s stock valued at $66,089,000 after purchasing an additional 119,295 shares in the last quarter. Hsbc Holdings PLC boosted its position in shares of Bio-Techne by 55.3% during the 4th quarter. Hsbc Holdings PLC now owns 261,370 shares of the biotechnology company’s stock valued at $20,166,000 after purchasing an additional 93,107 shares in the last quarter. TD Asset Management Inc increased its holdings in Bio-Techne by 9.7% in the fourth quarter. TD Asset Management Inc now owns 135,632 shares of the biotechnology company’s stock worth $10,465,000 after purchasing an additional 11,947 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in Bio-Techne by 152.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 32,378 shares of the biotechnology company’s stock valued at $2,498,000 after buying an additional 19,530 shares during the period. Institutional investors and hedge funds own 98.95% of the company’s stock.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.